After a two week baseline, 209 asthmatic children (mean age 10 years, range 6-17) were randomly allocated to receive 4 mg nedocromil sodium (n= 110) or placebo (n=99) four times daily for 12 weeks in addition to their current treatment. The children completed daily diary cards and visited the clinic at four week intervals. Statistically significant differences in favour of nedocromil sodium were seen for clinician assessment of asthma severity and diary card symptom scores, pulmonary function and inhaled P bronchodilator use. Total
symptom score decreased by 50/ofrom baseline in the nedocromil sodium group and by 9/o in the placebo group during the final four weeks. Nedocromil sodium was considered very or moderately effective by 78% of children/ parents (placebo 59%) and 73% of clinicians (placebo 50%). Nausea, headache and sleepiness, and dyspnoea led to withdrawal of one child from nedocromil sodium and placebo treatments, respectively. Reports of sore throat and headache were marginally greater with the nedocromil sodium treatment. It is concluded that nedocromil sodium was both effective and safe in the treatment of asthma in children. (Arch Dis Child 1993; 68:193-7) The effective management of bronchial asthma should allow a child to enjoy as near normal a lifestyle as possible and, as physicians, we have at our disposal a wide variety of treatments to help achieve this objective.' The antiallergic agent sodium cromoglycate, for example, has been in use for many years either as a first line treatment or in conjunction with inhaled P2
bronchodilators. We present here the results of an efficacy study of a new preventive agent for asthma.
Nedocromil sodium has been available for the treatment for adult asthma since the late 1980s. The body of research that has built up since its introduction indicates that its effectiveness is based on an anti-inflammatory mode of action.2' In addition to mast cell stabilising properties,5 6nedocromil sodium can prevent the activation of and release of mediators from inflammatory cells.7 8 
Results

PATIENT DEMOGRAPHICS
Sixty eight of the 277 children studied did not proceed beyond the baseline: the majority did not satisfy the criteria for entry into the treatment period, others were uncooperative, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] in children treated with placebo (fig 1) . Most of the improvement in the nedocromil sodium 34 group occurred during the first four weeks. Sixty eight (78%) of the children/parents reported that nedocromil sodium was a very or a moderately effective treatment (opinion scores 1 and 2) compared with 52 (59%) of the recipients of placebo (p<O01). Clinicians opinions were similar (p<O0Ol): nedocromil No significant between treatment differences were found in the pretreatment laboratory variables or in the changes from pretreatment to post-treatment. During the baseline seven children subsequently randomised to nedocromil sodium and three to placebo reported unusual symptoms (headache, cough, fever, pain, wheeze, and vomiting). During the treatment period, 24 nedocromil sodium and 30 placebo treated children reported at least one unusual symptom. Most frequently reported were pharyngeal/ tracheal symptoms (nedocromil sodium/placebo; 11/6), headache (4/1), cough (3/3), fever (3/3), bronchospasm/wheeze/dyspnoea (0/4), and eczema symptoms (2/2). One uncooperative child reported a 'bad taste' associated with placebo treatment.
Discussion
The results of our study present good evidence for the efficacy of nedocromil sodium in childhood asthma. Although near the lower limit, mean baseline PEF was within the normal range for these children. Mean FEV, was approximately 800/o of predicted normal for height and sex. Mean symptom scores and inhaled bronchodilator use were also low. Despite this, baseline monitoring indicated the potential for improvement, and during the treatment phase all diary card variables favoured nedocromil sodium. There were statistically significant treatment differences in favour of nedocromil sodium for total symptom score (and day and night time asthma scores), twice daily PEF measurements, and inhaled bronchodilator use. Clinician assessment of asthma severity and child/parent and clinician opinions of efficacy also significantly favoured nedocromil sodium. Clinic lung function, on the other hand, was not significantly improved.
Our findings of significant improvements in symptoms and bronchodilator use support the earlier research '8 19 in the more severe patient but also suport the potential use of nedocromil sodium in milder forms of disease.'7 Interestingly, a subanalysis of the effect of treatment on each child's worst baseline symptom showed significant improvements at each time point. Nedocromil sodium appeared to have a greater therapeutic effect in our study. Group size was much larger, however, thereby increasing the ability of the study to detect treatment differences.
In common with clinical experience with adults20 nedocromil sodium appears to be fairly rapid in onset of effect in children. Significant differences have been observed within two to three weeks. [17] [18] [19] In the present study the majority of the improvements in signs and symptoms occurred during the first four week period. A recent study has attempted to extend the observations of nedocromil sodium's inhibitory effect on cell activation in vitro to a controlled paediatric trial.26 Administration of nedocromil sodium for three months to asthmatic children led to a significant reduction in superoxide anion production by opsonised zymosan stimulated granulocytes. We are only aware of one similar study in adults in which nedocromil sodium, but not sodium cromoglycate, inhibited the abnormal in vitro response to aspirin of platelets from aspirin sensitive asthmatics. 27 Further ex vivo studies are needed to clarify the cellular action of nedocromil sodium in asthma.
In terms of our own results we can conclude that nedocromil sodium was able to improve daily asthma symptoms and lung function, concurrent with a significant reduction in daily bronchodilator intake, in children with mild to moderately severe disease.
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